Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses

• Published in: Molecular genetics and metabolism 2017-03, Vol.120 (3), p.247-254
• Main Authors: Kubaski, Francyne, Suzuki, Yasuyuki, Orii, Kenji, Giugliani, Roberto, Church, Heather J., Mason, Robert W., Dũng, Vũ Chí, Ngoc, Can Thi Bich, Yamaguchi, Seiji, Kobayashi, Hironori, Girisha, Katta M., Fukao, Toshiyuki, Orii, Tadao, Tomatsu, Shunji
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chromatography, Liquid; Dermatan Sulfate - blood; Dried Blood Spot Testing - methods; Female; Glycosaminoglycans; Glycosaminoglycans - blood; Hematopoietic stem cell transplantation; Heparitin Sulfate - blood; Humans; Infant; Infant, Newborn; Keratan Sulfate - blood; Male; Mucolipidoses; Mucolipidoses - diagnosis; Mucolipidoses - metabolism; Mucopolysaccharidoses; Mucopolysaccharidoses - diagnosis; Mucopolysaccharidoses - metabolism; Sensitivity and Specificity; Tandem Mass Spectrometry; Young Adult
• ISSN: 1096-7192; 1096-7206
• DOI: 10.1016/j.ymgme.2016.12.010

Mucopolysaccharidoses (MPSs) and mucolipidoses (ML) are groups of lysosomal storage disorders in which lysosomal hydrolases are deficient leading to accumulation of undegraded glycosaminoglycans (GAGs), throughout the body, subsequently resulting in progressive damage to multiple tissues and organs. Assays using tandem mass spectrometry (MS/MS) have been established to measure GAGs in serum or plasma from MPS and ML patients, but few studies were performed to determine whether these assays are sufficiently robust to measure GAG levels in dried blood spots (DBS) of patients with MPS and ML. In this study, we evaluated GAG levels in DBS samples from 124 MPS and ML patients (MPS I=16; MPS II=21; MPS III=40; MPS IV=32; MPS VI=10; MPS VII=1; ML=4), and compared them with 115 age-matched controls. Disaccharides were produced from polymer GAGs by digestion with chondroitinase B, heparitinase, and keratanase II. Subsequently, dermatan sulfate (DS), heparan sulfate (HS-0S, HS-NS), and keratan sulfate (mono-sulfated KS, di-sulfated KS, and ratio of di-sulfated KS in total KS) were measured by MS/MS. Untreated patients with MPS I, II, VI, and ML had higher levels of DS compared to control samples. Untreated patients with MPS I, II, III, VI, and ML had higher levels of HS-0S; and untreated patients with MPS II, III and VI and ML had higher levels of HS-NS. Levels of KS were age dependent, so although levels of both mono-sulfated KS and di-sulfated KS were generally higher in patients, particularly for MPS II and MPS IV, age group numbers were not sufficient to determine significance of such changes. However, the ratio of di-sulfated KS in total KS was significantly higher in all MPS patients younger than 5years old, compared to age-matched controls. MPS I and VI patients treated with HSCT had normal levels of DS, and MPS I, VI, and VII treated with ERT or HSCT had normal levels of HS-0S and HS-NS, indicating that both treatments are effective in decreasing blood GAG levels. Measurement of GAG levels in DBS is useful for diagnosis and potentially for monitoring the therapeutic efficacy in MPS. •DBS is feasible for GAG measurement by tandem mass spectrometry.•Untreated patients had higher GAG levels compared to control samples.•Treated patients had lower GAG levels compared to untreated patients.•GAG in DBS seem to be feasible for diagnosis and therapeutic monitoring.